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ABSTRACT
The ichthyoses, also known as disorders of keratinization (DOK), encompass a group of
genetic skin disorders linked by the common finding of abnormal barrier function, which
initiates a default compensatory pathway of hyperproliferation, resulting in the
characteristic clinical manifestation of localized or generalized scaling.
Ichthyoses are a highly heterogenous group of disorders, both genetically and clinically.
Despite the identification of causative mutations in over 50 genes, clear genotypephenotype correlations have been difficult to establish due to the rarity of the ichthyoses
and because mutations in the same gene can have widely divergent phenotypes, even
in individuals with the same disease-causing mutation.
In partnership with the Foundation for Ichthyosis and Related Skin Types (FIRST), we
have served as a major national and international referral center and recruited over 800
kindreds with DOK, utilizing whole exome sequencing to identify novel, rare mutations
that cause DOK, many of which represent phenotypic expansion.
We systematically evaluated genotypic and phenotypic data for 407 kindreds with
ichthyosis, the largest cohort published to date. We identified 156 novel mutations and
assessed phenotypic features of DOK with respect to genetic diagnosis to help refine
our understanding of this heterogeneous group of disorders (Chapter 1). Such a
systematic classification of DOK holds promise for the development of customized
management plans, generation of targeted therapeutics, and improved understanding of
prognostication based on genetic diagnosis.
In the process of performing a large scale genotype-phenotype characterization, we
identified kindreds with rare clinical subtypes of ichthyosis, including Bathing Suit
Ichthyosis (BSI), a rare disorder caused by mutations in the transglutaminase 1 gene
(TGM1) and characterized by the restriction of scale to sites of relatively higher
temperature such as the trunk, with cooler areas remaining unaffected (Chapter 2). We
identified novel and recurrent mutations in sixteen subjects with BSI, the largest cohort
published to date. Our findings expand the genotypic spectrum of BSI and the
understanding of temperature-sensitivity of TGM1 mutations. Increased awareness of
temperature-sensitive TGM1 genotypes should aid in genetic counseling, and provide
insights into the pathophysiology of TGM1 ichthyoses, and potential therapeutic
approaches.
In the course of unifying genetic and clinical data to advance the understanding of the
different subtypes of ichthyosis, we realized the critical importance of tools to assess the
clinical severity of ichthyosis. We designed a Visual Index for Ichthyosis Severity (VIIS)
and tested the instrument for reliability and reproducibility using two different settings:
one that utilized scoring of 60 test photographs by 10 dermatologists, and one with inperson evaluations on 85 subjects by 12 dermatologists at the Foundation for Ichthyosis
and Related Skin Types (FIRST) conference (Chapter 3). The validation process
revealed high reliability and reproducibility for both scale and erythema and indicated
that the VIIS performs better in person than with photographs, an important
consideration in design of clinical trials. This index provides a tool for clinical
phenotyping and assessment of therapeutic response for many disorders of
keratinization.
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INTRODUCTION

The ichthyoses are rare genetic skin disorders linked by the common finding of abnormal
barrier function, which leads to increased transepidermal water loss and compensatory
hyperproliferation. The unifying phenotypic feature of ichthyoses is localized or
generalized scaling. Other clinical manifestations can include erythema, palmoplantar
keratoderma (PPK), hypohydrosis, anhidrosis, and recurrent infections. DOK can have a
range of possible sequelae, including ectropion, or out-turning of the eyelids, alopecia,
deforming joint contractures, and failure to thrive Figure 1.

Figure 1 Sequelae of inherited ichthyoses
The range of possible sequelae of DOK includes a. Severe bilateral upper and lower
eyelid ectropion b. Scarring alopecia c. Failure to thrive requiring gastric tube placement
d. Deforming joint contractures e. Severe plantar keratoderma with resulting limitations
in ambulation. Genotype is provided in each panel.
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Although ichthyoses are primarily inherited disorders with onset at or shortly after birth,
rare acquired forms have been reported in the setting of malignancy, nutritional
deficiency, and autoimmune or infectious disease. Mutations in over 50 genes have
been reported to cause ichthyoses, and these affect a host of cellular functions including
DNA repair, lipid biosynthesis, adhesion, and desquamation as well as other pathways.1
Despite myriad pathways for pathogenesis, each features disrupted barrier function.

Epidermal barrier function is maintained by a regular pattern of epidermal renewal in
which keratinocytes, the primary cell type of the skin, arise from a renewing stem cell
pool and undergo a tightly regulated pattern of differentiation as they transit from the
innermost stratum basale to the outermost stratum corneum, where they are ultimately
sloughed off. This differentiation program is marked by site-specific expression of
proteins and, in the suprabasal layers, the production of components necessary for the
generation of the lipid barrier.

In the process of differentiation, keratins—intermediate filaments that are responsible for
the structural integrity of keratinocytes—are among the first proteins to be expressed in
a tightly regulated manner, with keratin 5 and 14 expressed in the basal layer and
keratin 1 and 10 expressed in the suprabasal layers. In stratum spinosum, the second
innermost layer of the epidermis, components of the lipid barrier (phospholipids,
cholesterol, sphingomyelin and glucosylceramides) are packaged into lamellar bodies,
which are specialized organelles that house the building blocks of the lipid barrier, as
well as enzymes essential to the processing of lipid barrier precursors. At the transition
from stratum granulosum—the third layer of the epidermis—to stratum corneum, the
contents of lamellar bodies are extruded into the intercellular space to form protective
lipid sheets that are responsible for the skin’s hydrophobic barrier. 2,3
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This overall process of differentiation results in the formation of a robust barrier in the
stratum corneum, composed of keratinocytes (the individual bricks of the barrier) and
inter-keratinocyte lipids (the mortar)4. Mutation in proteins essential to the formation of
this barrier (i.e. keratins, enzymes involved in lipid synthesis) lead to the disruption of
barrier integrity, resulting in ichthyosis.

Inherited ichthyoses exhibit marked genetic and phenotypic heterogeneity, and
advances in next-generation sequencing technology have allowed for more rapid and
cost-effective genetic analysis, leading to the identification of novel, rare mutations that
cause DOK. Clear large-scale genotype-phenotype correlations have been difficult to
establish, as mutations in the same gene can present with widely divergent phenotypes,
even within kindreds bearing the same disease-causing mutation.

In 2009, the Ichthyosis Consensus Conference established a consensus
classification for DOK based on pathophysiology, clinical manifestations, and mode of
inheritance1. This nomenclature system divides DOK into two main groups: 1)
nonsyndromic forms, with clinical findings limited to the skin 2) syndromic forms, with
involvement of other organ systems.

Nonsyndromic ichthyoses

Common Ichthyoses

Ichthyosis vulgaris (IV) and X-linked recessive ichthyosis (XLRI) are classified as the
“common ichthyoses”, given their high prevalence. IV is the most common form of
nonsyndromic inherited ichthyosis, with an estimated incidence of 1 in 250 births.5
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Typically, IV is a phenotypically mild form of ichthyosis. Clinical findings usually appear
around 2 months of age, and include generalized xerosis and fine white to gray scale
that is most prominent on the abdomen, chest and extensor surfaces of the extremities.
Keratosis pilaris and hyper-linearity of the palms and soles are also frequently
associated with IV.

IV is caused by autosomal dominant mutations in the filaggrin gene (FLG), which plays
an essential role in epidermal differentiation and formation of the skin barrier. 6,7 An
autosomal semidominant mode of inheritance has also been described, meaning that
while individuals with heterozygous mutations have a mild phenotype, those with
homozygous or compound heterozygous mutations can display more severe forms of
ichthyosis.6

Patients with IV are at increased risk for atopic dermatitis, asthma and allergies.8,9 This
increased risk is likely due to disruption of barrier function, which may allow for greater
penetration of the epidermis by potential allergens.8

XLRI is the second most common form of inherited ichthyoses, with a prevalence of
1:2000 to 1:6000 males.10 Clinical findings in XLRI are frequently indistinguishable from
IV. Manifestations usually first appear in the neonatal period as generalized
desquamation and xerosis, and progress to fine scaling of the trunk and extremities in
infancy. Over time, patients develop brownish, polygonal, plate-like scale that is tightly
adherent to the skin. XLRI is caused by mutations in the STS gene, encoding steroid
sulfatase, on the X chromosome.11
Autosomal Recessive Congenital Ichthyosis
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Autosomal Recessive Congenital Ichthyosis (ARCI) is a genetically and phenotypically
heterogenous group of disorders that includes harlequin ichthyosis (HI), lamellar
ichthyosis (LI), and congenital ichthyosiform erythroderma (CIE). The incidence of ARCI
has been approximated at 1 in 200,000 births.12

HI is caused by loss-of-function mutations in ABCA12, which encodes an ATP binding
cassette (ABC) transporter. ABCA12 is necessary for lipid transport into lamellar
granules, and central to the process of cornification and lipid barrier formation.13
Interestingly, while homozygous loss of function mutations in ABCA12 lead to HI,
missense mutations in ABCA12 result in milder phenotypes on the LI/CIE spectrum.14
Neonates with HI present with thick, armor-like scale with severe ectropion (eversion of
the eyelids), eclabium (eversion of the lips), and flattening of the ears. Some patients
with HI die during the neonatal period, but survival has been shown to improve with
progress in neonatal intensive care and early treatment with systemic retinoids. Rajpopat
et al. showed that 83% of HI patients treated with oral retinoids survived compared to
24% of untreated patients.15

LI and CIE represent a spectrum of disorders caused by mutations in one of nine genes:
TGM1, NIPAL4/ICHTHYIN, ALOX12B, ALOXE3, CYP4F22, ABCA12, PNPLA1, CERS3,
and LIPN.16 Mutations in TGM1 are the most common, and account for approximately
32% of heritability of ARCI.17 Fischer et al. found that mutations in the five most common
genes (TGM1, NIPAL4, ALOX12B, CYP4F22, ALOXE3, and ABCA12) account for 78%
of ARCI cases.17 Despite this, prior studies of large cohorts of patients with ARCI
showed that 22-40% of patients have no mutations in known genes,17,18 highlighting the
heterogeneity of this group of disorders and the importance of continued efforts in gene
discovery.
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Keratinopathic Ichthyosis

Keratinopathic ichthyosis is a group of disorders caused by mutations in the keratin
family of genes. The major variant of keratinopathic ichthyosis is epidermolytic ichthyosis
(EI). Minor variants include superficial epidermolytic ichthyosis (SEI), annular
epidermolytic ichthyosis (AEI) and ichthyosis Curth-Macklin.

EI is caused by autosomal dominant mutations in the keratin 1 (KRT1) and keratin 10
(KRT10) genes, which play an essential role in maintaining structural integrity in
suprabasal keratinocytes19. EI is characterized by marked skin fragility, leading to
generalized blister formation on a background of erythroderma. Neonates present with
blistering and erythema at birth, but symptoms improve over time. Blistering becomes
less frequent and is usually confined to sites of trauma in adulthood. Palmoplantar
keratoderma is often associated with EI, although it is more commonly seen in patients
with mutations in KRT1 than KRT10.19

SEI, also known as ichthyosis bullosa of Seimens, is caused by mutations in KRT2.20,21
Phenotypic manifestations are milder compared to EI, and include blister formation in
response to trauma and hyperkeratosis (thickening of the stratum corneum) over flexural
areas.

AEI is a rare phenotypic variant of EI that was shown by Yang et al. to be caused by a
unique mutation in KRT10 that replaces an alanine at residue 12 with a proline.22 It is
characterized by blister formation at birth, which later progresses to the intermittent
development of annular polycyclic erythematous plaques on the truck and extremities.
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Ichthyosis Curth-Macklin is another rare disorder and is caused by autosomal dominant
mutations in KRT1.23,24 It is characterized by extensive spiky or verrucous hyperkeratosis
over the trunk and extensor surfaces of the extremities. It may also be associated with
severe palmoplantar keratoderma. In the past five years, 2 novel distinct causative
mutations in KRT1 have been identified, in addition to the two mutations that were
initially described.25,26 While both EI and Ichthyosis Curth-Macklin can be caused by
mutations in KRT1, EI is caused by amino acid substitutions and in-frame deletions in
the gene,27 while ichthyosis Curth-Macklin is caused by insertions or deletions that lead
to a frameshift.23-26

Syndromic ichthyoses

In addition to cutaneous involvement, syndromic ichthyoses affect at least one other
organ or system. Many causative genes have been identified for syndromic ichthyoses,
including NSDHL (CHILD syndrome),28 EBP (Conradi-Hunermann-Happle syndrome,
CHILD Syndrome),28,29 and ALDH3A2 (Sjogren-Larsson syndrome).30 Depending on the
specific gene mutated, a wide range of organ systems can be involved, including the
skeletal, nervous, endocrine, and cardiovascular systems. Many of the syndromic
ichthyoses may present at birth with isolated cutaneous findings, highlighting the
importance of a high degree of clinical suspicion and the usefulness of genetic analysis
in early diagnosis of these syndromic cases.31

Study of ichthyosis in Dr. Choate’s lab

In partnership with the Foundation for Ichthyosis and Related Skin Types (FIRST), we
have served as a major national and international referral center and recruited over 800
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kindreds with DOK, utilizing whole exome sequencing to identify novel, rare mutations
that cause DOK, many of which represent phenotypic expansion. We see patients with
ichthyosis at a monthly ichthyosis clinic, as well as the FIRST family conferences, which
bring together families from across the country and around the world, and provide
access to information, expert advice, and opportunities for families to get involved in
research. We had the pleasure of organizing a research program for the FIRST family
conference in San Diego in 2016, where we evaluated over 150 families with ichthyosis,
providing genetic testing, and enrolling families in the National Registry. To assess
phenotypic manifestations of disease and analyze genotype-phenotype
characterizations, we took standardized clinical photographs of all enrolled subjects, with
the goal of capturing cardinal phenotypic features of disease. Examples of the
standardizes poses used for photography are shown in Figure 2.

This detailed database of genotypic, phenotypic, and clinical data for patients with
ichthyosis has allowed us to conduct a large-scale genotype-phenotype characterization
for 407 kindreds with ichthyosis, the largest cohort published to date. We identified 156
novel mutations and assessed phenotypic features of DOK with respect to genetic
diagnosis to help refine our understanding of this heterogeneous group of disorders
(Chapter 1). In the process of performing a large scale genotype-phenotype
characterization, we identified kindreds with rare clinical subtypes of ichthyosis, including
Bathing Suit Ichthyosis (BSI), a rare disorder caused by mutations in transglutaminase 1
(TGM1) and characterized by the restriction of scale to sites of relatively higher
temperature such as the trunk, with cooler areas remaining unaffected (Chapter 2). We
identified novel and recurrent mutations in sixteen subjects with BSI, the largest cohort
published to date. Our findings expand the genotypic spectrum of BSI and the
understanding of temperature-sensitivity of TGM1 mutations.
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In the course of unifying genetic and clinical data to advance the understanding of the
different subtypes of ichthyosis, we realized the critical importance of tools to assess the
clinical severity of ichthyosis. We designed a Visual Index for Ichthyosis Severity (VIIS)
and tested the instrument for reliability and reproducibility (Chapter 3). This index
provides a tool for clinical phenotyping and assessment of therapeutic response for
many disorders of keratinization.
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Figure 2 Standardized photography for documentation of clinical findings. Subject
with recessive ichthyosis due to homozygous ABCA12 mutation demonstrating standard
poses for high resolution photography.
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STATEMENT OF PURPOSE

1. To perform a large scale genotype-phenotype characterization for 407 kindreds with
ichthyosis, identifying novel mutations and systematically evaluating phenotypic features
of ichthyosis with respect to genetic diagnosis to refine our understanding of this rare
group of disorders.

2. Within our cohort, to identify rare subtypes of ichthyosis, including Bathing Suit
Ichthyosis (BSI), which is characterized by restriction of scale to sites of relatively higher
temperature such as the trunk, with cooler areas remaining unaffected. To identify novel
and recurrent mutations for our cohort of subjects with BSI, expanding our
understanding of temperature-sensitive mutations.

3. To design and validate a severity index for ichthyosis, a critical tool for evaluating the
efficacy of new treatments and advancing research in ichthyosis.
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Chapter 1: Genotype-Phenotype Correlations and Novel Mutations in 407
Ichthyosis Kindreds

ABSTRACT

We identify novel mutations and systematically evaluate phenotypic features of DOK
with respect to genetic diagnosis in a cohort of 407 kindreds with ichthyosis, the largest
cohort published to date. We recruited over 800 subjects with ichthyoses, and performed
gene screening, with exome sequencing employed in the remaining mutation-unknown
cases. Clinical photographs were taken to capture phenotypic involvement and
questionnaires were utilized to assess additional clinical manifestations. We identified a
total of 156 novel mutations, expanding the genotypic spectrum of this group of rare
disorders. Our systematic classification of phenotypic manifestations revealed cardinal
features that are associated with mutations in each gene, as well as the phenotypic
range seen within our cohort for each gene. Our analysis of clinical manifestations
revealed that the majority of subjects with ichthyosis are born with a collodion membrane
(69%), and identified pruritis (90%), skin pain (70%), anhidrosis (57%), and eye
problems (57%) as common clinical features. Such a systematic classification holds
promise for the development of customized management plans, generation of targeted
therapeutics, and improved understanding of prognostication based on genetic
diagnosis.

METHODS
I verified the Sanger sequencing traces for all of the mutations in the cohort, identifying
single nucleotide polymorphism (SNPs), referencing mutations previously reported in the
HGMD Professional Database and in the Exome Aggregation Consortium, and
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determining which mutations are novel. Working with members of the Choate lab, I
organized a research program for the Foundation for Ichthyosis and Related Skin Types
(FIRST) Conference, where I recruited and consented patients, took clinical
photographs, and obtained saliva samples for genetic analysis. I also recruited and
consented patients, taking standardized clinical photographs and obtaining saliva
samples, monthly at the ichthyosis clinic. I performed all of the genotype-phenotype
correlations reported in the study, evaluating phenotypic features of the clinical
photographs taken for our patients, assessing both cardinal features and phenotypic
range, and creating the figures of phenotypic manifestations. I also evaluated clinical
features by analyzing the in-depth questionnaires filled out by patients at the FIRST
conference and at the monthly ichthyosis clinic. Part of accomplishing this task involved
curating the paper questionnaires, and I led the effort of creating an online Oncore
database and transferring the information into a format that would facilitate analysis.
Using the database, I then performed the analysis on the clinical manifestations of
ichthyosis, which is reported in this study. The genetic analysis reported in this study
was performed by various members of the Choate lab.

Subjects and samples
The study was approved by the Yale Human Investigation Committee, consistent with
the Declaration of Helsinki guidelines, and written informed consent was obtained from
the subjects or their parents. Subjects with X-linked ichthyosis and ichthyosis vulgaris,
as determined by family history and clinical manifestations and confirmed by genetic
analysis, were excluded from the study. A total of 427 subjects and 407 kindreds were
included in the study.
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Each subject (or parent in the case of a child) was asked to complete a detailed
questionnaire, including self-reporting of the phenotype at birth, clinical involvement, and
associated systemic manifestations. Fully completed questionnaires were obtained from
135 subjects. For subjects seen at the Foundation for Ichthyosis and Related Skin Types
(FIRST) family conference, standardized clinical photographs were taken to capture the
phenotypic involvement. For figures illustrating the phenotypic range, only subjects who
were not on systemic or topical retinoid therapy were included in order to more
accurately capture the underlying disease severity. Saliva or blood samples were
obtained from all of the subjects for genetic analysis.

Genetic Analysis
Genetic analysis was performed on DNA isolated from the saliva or blood of index cases
and both parents, if available. Genomic DNA was extracted using standard procedures.
Samples were first screened for mutations in 48 genes (AAGAB, ABCA12, ABHD5,
ALOXE3, ALOX12B, ALDH3A2, ATP2A2, ATP2C1, AQP5, CARD14, CDSN, CERS3,
CLDN1, CYP4F22, DKC1, DSC2, DSG1, DSP, EBP, EDA, FLG, GJA1, GJB2, GJB3,
GJB4, GJB6, KANK2, KRT1, KRT10, KRT2, KRT9, KRT16, KRT17, KRT6C, MBTPS2,
NIPAL4, NSDHL, PNPLA1, POGLUT1, RHBDF2, RSPO1, SERPINB7, SNAP29,
SLC27A4, SPINK5, STS, TGM1, TRPV3) via multiplex polymerase chain reaction (PCR)
and next generation sequencing. Mutations identified by next generation sequencing
were verified by Sanger sequencing. If no causative mutation was identified through this
screening panel, exome sequencing was employed, allowing for identification of novel,
rare causes of DOK.

All novel mutations reported in this manuscript are not referenced as single nucleotide
polymorphisms (SNPs) and were not found in the HGMD Professional Database
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(http://www.hgmd.cf.ac.uk) or in the Exome Aggregation Consortium
(http://exac.broadinstitute.org).

RESULTS

Self-reported demographic characteristics for subjects included in the study (n=427
subjects) are shown in Table 1 and genotypic information described in Table 2. 298
kindreds were found to have autosomal recessive mutations in 21 different genes, and
109 kindreds had autosomal dominant mutations in 17 genes. Clinical characteristics for
subset of 135 subjects who completed a detailed questionnaire are shown in Table 3.
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Gender

Ethnicity

Age

Male

196

45.9%

Female

225

52.7%

Unclassified

6

1.4%

Caucasian

181

42.4%

Hispanic/Latino

65

15.2%

Asian

36

8.4%

Middle Eastern

24

5.6%

Black

18

4.2%

Mixed

3

0.7%

Native American

1

0.2%

Unclassified

99

23.2%

≥ 18 yrs

155

36.3%

< 18

190

44.5%

Unclassified

82

19.2%

Table 1 Demographic characteristics for all subjects included in the study (n=427
subjects)
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a.

b.

GENE

TOTAL
KINDREDS

HET

HOM

NOVEL
MUTATIONS

GENE

TOTAL
KINDREDS

NOVEL
MUTATIONS

TGM1

110

75

35

24

KRT10

55

11

ABCA12

39

34

5

34

KRT1

17

7

ALOX12B

38

30

8

25

KRT2

9

2

NIPAL4

33

7

26

3

CARD14

5

3

ALOXE3

19

8

11

7

GJB2

5

0

PNPLA1

12

3

9

8

DSP

3

0

SPINK5

12

8

4

6

GJA1

3

0

CYP4F22

11

4

7

8

ATP2C1

1

1

ALDH3A2

5

2

3

2

ATP2A2

1

0

ABHD5

4

1

3

0

GJB3

2

1

MBTPS2

3

0

3

1

EBP

1

1

CDSN

2

0

2

2

GJB4

1

0

CERS3

2

1

1

1

DSG1

1

1

CLDN1

1

0

1

1

KRT6B

1

1

CSTA

1

0

1

1

POGLUT1

1

1

KANK2

1

0

1

1

RHBD2

1

0

LIPH

1

0

1

0

TRPV3

1

0

RSPO1

1

0

1

1

ZDHHC4

1

1

SLC27A4

1

1

0

0

109

30

SNAP29

1

0

1

0

ST14

1

1

0

1

298

175

123

126

c.
2%
3%
3%
3%
4%

13%

27%

5%
8%

13%
9% 10%

TGM1
KRT10
ABCA12
ALOX12B
NIPAL4
ALOXE3
KRT1
PNPLA1
SPINK5
CYP4F22
KRT2
OTHER

Table 2 Genotypic characteristics for all kindreds included in the study (n=407
kindreds)
a. Genes with autosomal recessive pattern of inheritance, b. Genes with autosomal
dominant pattern of inheritance, c. Pie chart of the most common genes in our cohort.
Abbreviations: HET, kindreds with compound heterozygous mutations; HOM, kindreds
with homozygous mutations
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n

Collodion
membrane

Skin
pain

Pruritis

Skin
odor

Skin
infections

Anhidrosis

Hearing
problems

Eye
problems

Hair
loss

TGM1

45

ALOX12B

20

NIPAL4

15

ABCA12

13

ALOXE3

8

CYP4F22

8

KRT10

20

KRT1

6

87%
(39/45)
100%
(18/18)
50%
(7/14)
50%
(6/12)
71%
(5/7)
100%
(8/8)
14%
(2/14)
17%
(1/6)
69%

58%
(25/43)
65%
(11/17)
87%
(13/15)
77%
(10/13)
63%
(5/8)
29%
(2/7)
95%
(18/19)
100%
(4/4)
70%

93%
(39/42)
89%
(16/18)
87%
(13/15)
100%
(13/13)
75%
(6/8)
86%
(6/7)
83%
(15/18)
100%
(4/4)
90%

43%
(19/44)
30%
(6/20)
47%
(7/15)
54%
(7/13)
25%
(2/8)
50%
(4/8)
89%
(17/19)
100%
(6/6)
51%

47%
(21/45)
35%
(7/20)
20%
(3/15)
23%
(3/13)
50%
(4/8)
38%
(3/8)
85%
(17/20)
33%
(2/6)
44%

86%
(6/42)
88%
(14/16)
80%
(12/15)
69%
(9/13)
71%
(5/7)
88%
(7/8)
82%
(14/17)
66% (4/6)

62%
(28/45)
32%
(6/19)
40%
(6/15)
62%
(8/13)
38%
(3/8)
25%
(2/8)
30%
(6/20)
16%
(1/6)
45%

74%
(31/42)
47%
(9/19)
60%
(9/15)
69%
(9/13)
75%
(6/8)
38%
(3/8)
35%
(7/20)
16%
(1/6)
57%

51%
(22/43)
21%
(4/19)
7%
(1/15)
54%
(7/13)
43%
(3/7)
25%
(2/8)
20%
(4/20)
16%
(1/6)
34%

135

57%

Table 3 Clinical characteristics for a subset of subjects who completed a
questionnaire (n=135 subjects)
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Autosomal recessive mutations
Similar to prior findings,17, 32 mutations in TGM1 are the most common in our cohort,
accounting for 37% of heritability of the autosomal recessive cases and 27% of
heritability of all cases within our cohort. Mutations in the 5 most common genes (TGM1,
ABCA12, ALOX12B, NIPAL4, ALOXE3) account for 80% of the heritability of the
autosomal recessive cases. Genotype-phenotype characterizations for the 5 most
common autosomal recessive genes are discussed below.

TGM1
The TGM1 gene encodes tranglutaminase-1, which is an enzyme essential for the crosslinking of proteins during the formation of the cornified envelope.33, 34 Our cohort includes
a total of 110 kindreds with mutations in TGM1, 75 with compound heterozygous
mutations and 35 with homozygous mutations. We identified 24 mutations in TGM1 that
are novel and have not been described previously.

Phenotypic features of subjects with mutations with TGM1 are shown in Figure 3.
Cardinal features of ichthyosis caused by mutations in TGM1 include flat armor-like
plates of scale, with varying degree of mild to moderate erythema.

Most subjects with mutations in TGM1 were born with a collodion membrane (87%,
n=45). Common clinical features include pruritis (93%, n=42), anhidrosis (86%, n=42),
eye problems (74%, n=42), and hearing problems (62%, n=45). The majority of patients
reported skin pain (58%, n=43) and alopecia (51%, n=43).
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Figure 3 Phenotypic features of subjects with mutations in TGM1
a. Cardinal features include flat armor-like plates of scale, with mild to moderate
erythema b. Phenotypic manifestations range from discontinuous smoothening
(diminished fine skin markings, shininess) with small scales (left) to confluent, large
thick scales (right).
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ABCA12
The ABCA12 gene encodes an ATP-binding cassette (ABC) transporter that is crucial for
the energy-dependent lipid transport into lamellar bodies and the integrity of the lipid
barrier.35 Homozygous loss-of-function mutations in ABCA12 result in harlequin
ichthyosis, a severe form of ichthyosis characterized by neonatal encasement in a thick,
armor-like scale with associated findings of eclabium, ectropion and flattened ears.
Missense mutations in the gene result in milder phenotypes on the lamellar ichthyosis
(LI) and congenital ichthyosiform erythema (CIE) spectrum.

Our cohort includes a total of 39 kindreds with mutations in ABCA12 (13% of heritability
of autosomal recessive cases), 34 with compound heterozygous mutations and 5 with
homozygous mutations. Six subjects had truncating mutations in both alleles, resulting in
harlequin ichthyosis. We identified 34 mutations in ABCA12 that are novel and have not
been described previously. Cardinal features of ichthyosis caused by mutations in
ABCA12 (Figure 4) include significant (often severe) erythema with fine scale and
variable PPK, as well as the characteristic findings of tapering digits and hyperconvex
nails. Interestingly, all of the subjects in Figure 4 are compound heterozygous with one
missense and one nonsense mutation. Despite this, a varying degree of erythema (mild
to severe) is observed.

Half of the subjects with mutations in ABCA12 were born with a collodion membrane
(50%, n=12). Common clinical features include pruritis (100%, n=13), skin pain (77%,
n=13), anhidrosis (69%, n=13), eye problems (69%, n=13), and hearing problems (62%,
n=13). The majority of patients reported skin odor (54%, n=13) and alopecia (54%,
n=13).
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Figure 4 Phenotypic features of subjects with mutations in ABCA12
a. Cardinal features include significant (often severe) erythema with fine scale and
variable PPK, as well as the characteristic findings of tapering digits and hyperconvex
nails. b. Phenotypic manifestations range from mild erythema, discontinuous
smoothening with small scales (left) to severe erythema with confluent scales (right). Of
note, both subjects in panel b are compound heterozygous with one missense and one
nonsense mutation.
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ALOX12B and ALOXE3

The ALOX12B and ALOXE3 genes encode the lipoxygenases 12R-LOX (12Rlipoxygenase) and eLOX-3 (epidermis-type lipoxygenase 3), respectively. The
consecutive action of these enzymes leads to the oxygenation of ceramides, which are
essential to the formation of the lipid barrier.36, 37

Our cohort includes a total of 38 kindreds with mutations in ALOX12B (13% of heritability
of autosomal recessive cases) and 19 kindreds with mutations in ALOXE3 (6% of
heritability of autosomal recessive cases). We identified 25 novel mutations in ALOX12B
and 7 novel mutations in ALOXE3.

Given that the products of ALOX12B and ALOXE3 function within the same pathway, it
is not surprising that the phenotypic manifestations caused by mutations in these 2
genes share common features (Figures 5 and 6). Cardinal features of ichthyosis
caused by mutations in ALOX12B and ALOXE3 include fine scale, absence of PPK, and
mild erythema in some subjects.

Most subjects with mutations in ALOX12B and ALOXE3 were born with a collodion
membrane (100% ALOX12B, n=18; 71% ALOXE3, n=7). Common clinical features
include pruritis (89% ALOX12B; 75% ALOXE3), skin pain (65% ALOX12B; 63%
ALOXE3), anhidrosis (88% ALOX12B; 71% ALOXE3), and eye problems (47%
ALOX12B; 75% ALOXE3).
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Figure 5 Phenotypic features of subjects with mutations in ALOX12B
a. Cardinal features include fine scale, absence of PPK, and mild erythema in some
subjects b. Phenotypic manifestations range from discontinuous smoothening and
small, fine scale (left) to confluent fine scale and more significant erythema (right).
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Figure 6 Phenotypic features of subjects with mutations in ALOXE3
Similar to mutation in ALOX12B, cardinal features include fine scale, absence of PPK,
and minimal to mild erythema. These features are fairly consistent within our cohort,
with minimal variation among subjects.
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NIPAL4
The NIPAL4 gene encodes the NIPA-like domain containing 4 protein, thought to
function as an Mg2+ transporter and be involved in lipid processing and lamellar body
formation.38

Our cohort includes a total of 33 kindreds with mutations in NIPAL4 (11% of heritability
of autosomal recessive cases), 7 with compound heterozygous mutations and 26 with
homozygous mutations. We identified 3 mutations in NIPAL4 that are novel and have not
been described previously.

Cardinal features of ichthyosis caused by mutations in NIPAL4 (Figure 7) include fine
scale, absence of PPK, and a varying degree of erythema. Similar to prior findings,39 the
A176D missense mutation was common in subjects with mutations in NIPAL4,
representing 55 of the 66 alleles (83%) examined in our cohort. Interestingly, while 3 of
the subjects in Figure 5 are homozygous for the A176D mutation, great variations in the
degree of scale and erythema are observed in these subjects.

Half of the subjects with mutations in NIPAL4 were born with a collodion membrane
(50%, n=14). Common clinical features include pruritis (87%, n=15), skin pain (87%,
n=15), anhidrosis (80%, n=15), eye problems (60%, n=15).
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Figure 7 Phenotypic features of subjects with mutations in NIPAL4
a. Cardinal features include fine scale, absence of PPK, and a varying degree of
erythema b. Phenotypic manifestations range from barely perceptible pink erythema
and discontinuous smoothening (left) to deep red-purple erythema with confluent
smoothening and scale (right). Of note, all subjects depicted in this figure are
homozygous for NIPAL4 A176D.

Marukian 32
Autosomal dominant mutations
Keratinopathic ichthyosis, a group of disorder caused by mutations in one of the keratin
genes, accounts for 74% of the heritability of the autosomal dominant cases. Keratins
are intermediate filaments that are essential to the formation of the cytoskeleton network
and maintenance of epidermal integrity. Mutations in KRT10 and KRT1 are the most
common among the autosomal dominant cases in our cohort, accounting for 50% and
16% of the heritability, respectively. These 2 genes are essential to the structural
integrity of the suprabasal epidermis.40

Mutations in KRT10 and KRT1 most commonly result in epidermolytic ichthyosis (EI),
characterized by diffuse erythroderma and skin fragility with blister formation during the
neonatal period, evolving into hyperkeratosis and blistering at sites of trauma in
adulthood. Ichthyosis Curth-Macklin is a rare phenotypic variant caused by mutations in
KRT1, characterized by spine-like or verrucous hyperkeratosis. While mutations in KRT1
can result in both EI and ichthyosis Curth-Macklin, EI is caused by missense mutations
and in-frame deletions,41 while Curth-Macklin is caused by frameshift mutations.42-45

Genotype-phenotype characterizations for KRT10 and KRT1 are discussed in more
detail below.

KRT10
Our cohort includes a total of 55 kindreds with mutations in KRT10, all with heterozygous
mutations. We identified 11 mutations in KRT10 that are novel and have not been
described previously.
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Phenotypic features of subjects with EI with mutations in KRT10 are shown in Figure 8.
Cardinal features of EI caused by mutations in KRT10 include columnar hyperkeratosis,
scale in which the vertical dimension approaches or exceeds the horizontal dimension
(compared to flat scale seen in cases caused by mutations in one of the autosomal
recessive gene, such as TGM1). Skin fragility is another cardinal feature, especially at
sites of trauma. As shown in Figure 8, there may be a variable degree of underlying
erythema. PPK is typically present and smooth with occasional focal accentuation.

A minority of subjects with mutations in KRT10 were born with a collodion membrane
(14%, n=14). Common clinical features include skin pain (95%, n=19), skin odor (89%,
n=19), skin infections (85%, n=20), pruritis (83%, n=18), and anhidrosis (82%, n=17)
Hearing problems (30%, n=20), eye problems (35%, n=20), and alopecia (20%, n=20)
were less common.
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Figure 8 Phenotypic features of subjects with mutations in KRT10
a. Cardinal features include columnar hyperkeratosis, skin fragility, and PPK b. Skin
findings range from discontinuous regions of hyperkeratotic surface accentuation,
including organized or geometric exaggeration of coarse skin markings (left) to
confluent, primarily columnar hyperkeratosis (right) c. PPK is typically present and
smooth with occasional focal accentuation.
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KRT1
Our cohort includes a total of 17 kindreds with mutations in KRT1, all with heterozygous
mutations. We identified 7 mutations in KRT1 that are novel and have not been
described previously.

Phenotypic features of subjects with mutations with KRT1 are shown in Figure 9.
Cardinal features of EI caused by mutations in KRT1 include columnar hyperkeratosis,
with significant involvement of the extensor surfaces of joints in some subjects. PPK is
more severe in subjects with EI caused by mutations in KRT1 than KRT10.

A minority of subjects with mutations in KRT1 were born with a collodion membrane
(17%, n=6). Common clinical features include skin pain (100%, n=4), skin odor (100%,
n=6), pruritis (100%, n=4), and anhidrosis (66%, n=4).
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Figure 9 Phenotypic features of subjects with mutations in KRT1
a. Cardinal features include columnar hyperkeratosis, skin fragility, and severe PPK b.
Skin findings range from pink erythema with columnar hyperkeratosis (left) to confluent,
organized or geometric exaggeration of coarse skin markings with pink erythema and
marked skin fragility (right) c. PPK is severe in most cases.
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DISCUSSION

This study, which reports the genotype and phenotype data for 407 kindreds with
ichthyosis, represents the largest cohort published to date. We have identified a total of
156 novel mutations, expanding the genotypic spectrum of this group of rare disorders.

While prior studies have reported on the spectrum of phenotypic and genotypic findings
in ichthyoses,32,46-49 most were limited to specific ethnic groups and focused on particular
ichthyosis subgroups. We aimed to capture the comprehensive spectrum of genotypes
and phenotypes seen in ichthyosis, and reported data on an ethnically heterogeneous
cohort with representation of all of the major genes involved in ichthyosis.

The genotype-phenotype correlations in ichthyoses are complex, with significant
variations in phenotypic severity and extent of clinical manifestations in subjects with
mutations in the same gene. Within our cohort, even subjects bearing the same disease
causing mutation (e.g. subjects homozygous for NIPAL4 A176D) presented with a
spectrum of phenotypic severity, with varying degrees of both erythema and scale. This
finding highlights the need for further research to elucidate the impact of genetic
modifiers and/or environmental factors that may affect disease severity.

Given the intrinsic complexities of genotype-phenotype correlations in ichthyoses, we
aimed to capture the cardinal phenotypic features of each of the major genes, while
providing the range of disease severities present in our cohort for a given gene. The
ability to differentiate potential causative genes based on key phenotypic features may
allow for utilization of the more time- and cost-efficient targeted sequencing of the
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candidate gene(s), rather than sequencing a panel of ichthyosis genes or pursuing
whole-exome sequencing.

To our knowledge, this study is the first to characterize clinical features of ichthyosis
based on the specific gene mutated. Hellstrom Pigg et al. reported frequencies of clinical
features for the different clinical subtypes of Autosomal Recessive Congenital Ichthyosis
(Harlequin Ichthyosis, Lamellar Ichthyosis, Congenital Icthyosiform Erythroderma, and
Pleomorphic Ichthyosis);32 however, there is much phenotypic overlap among these
different clinical subtypes and there has been an effort to move away from clinical
classification and utilize ichthyosis groupings based on the gene affected.1 Our analysis
showed that the majority of subjects with ichthyosis are born with a collodion membrane
(69%, n=135), and identified pruritis (90%), skin pain (70%), anhidrosis (57%), and eye
problems (57%) as common clinical manifestations. Certain findings were more common
in subjects with specific genotypes, including skin odor in subjects with mutations in
KRT10 and KRT1 (89% and 100%, respectively), and hearing problems with subjects
with mutations in TGM1 and ABCA12 (62% for both).

Our findings expand the mutation spectrum of ichthyoses and contribute to the
understanding of the relationship between the genotype and the phenotypic and clinical
findings. Such a systematic classification holds promise for the development of
customized management plans that account for mutation-specific morbidities, and
improved understanding of prognostication based on the genetic diagnosis.
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Chapter 2: Expanding the Genotypic Spectrum of Bathing Suit Ichthyosis

ABSTRACT
Bathing Suit Ichthyosis (BSI) is a rare congenital disorder of keratinization, characterized
by restriction of scale to sites of relatively higher temperature such as the trunk, with
cooler areas remaining unaffected. Fewer than 40 cases have been reported in the
literature. BSI is caused by recessive, temperature-sensitive mutations in
transglutaminase 1 (TGM1). Clear genotype-phenotype correlations have been difficult
to establish, as several TGM1 mutations have been reported both in BSI and other forms
of congenital ichthyosis. We identify novel and recurrent mutations in sixteen subjects
with BSI, the largest cohort published to date. We report eight TGM1 missense
mutations that have not been previously found in BSI; five have been previously
described in non-temperature sensitive forms of congenital ichthyosis (Arg143Cys,
Gly218Ser, Gly278Arg, Arg286Gln, Ser358Arg) and three (Tyr374Cys, Phe495Leu,
Ser772Arg) are novel mutations. Three probands are homozygous for Arg264Trp,
Arg286Gln, or Arg315Leu, indicating that these mutations are temperature-sensitive.
Seven of ten probands with a compound heterozygous TGM1 genotype have a mutation
at either arginine 307 or 315, providing strong evidence that mutations at these sites are
temperature-sensitive, and highlighting the importance of these residues in the
pathogenesis of BSI. Our findings expand the genotypic spectrum of BSI and the
understanding of temperature-sensitivity of TGM1 mutations. Increased awareness of
temperature-sensitive TGM1 genotypes should aid in genetic counseling, and provide
insights into the pathophysiology of TGM1 ichthyoses, transglutaminase 1 enzymatic
activity, and potential therapeutic approaches.
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INTRODUCTION
Autosomal recessive congenital ichthyosis (ARCI) comprises a spectrum of disorders.
The major phenotypic subtypes of ARCI include lamellar ichthyosis (LI), congenital
ichthyosiform erythroderma (CIE), and harlequin ichthyosis (HI). While ARCI is
genetically heterogeneous with at least 9 different genes causative for the most common
forms,16 approximately 30% of the heritability of ARCI is explained by mutations in
TGM1.17 TGM1 encodes transglutaminase 1 (TGase-1), an enzyme involved in the
formation of the cornified envelope.33

While mutations in TGM1 most commonly cause a spectrum of LI and CIE phenotypes
of varying severity, they also underlie bathing suit ichthyosis (BSI). BSI, a very rare form
of ARCI with fewer than 40 reported cases, is characterized by lamellar scaling that is
restricted primarily to the truck, neck and scalp. Affected infants are typically born as
collodion babies and develop more localized scaling after shedding of the membrane.
BSI is due to the temperature sensitivity of certain TGM1 mutations.50 To date clear
genotype-phenotype correlations have been difficult to establish due to the rarity of BSI
and because many of the BSI mutations have also been reported in subjects with more
generalized forms of ARCI.

We identified sixteen subjects with BSI and, employing targeted sequencing, found
mutations in TGM1 in each case. Herein we report phenotypic and genotypic data for
this cohort. We identified eight missense mutations newly associated with BSI, including
three novel mutations, and employed these genotypes to make inferences about the
temperature sensitivity of TGM1 mutations. Our findings expand the spectrum of TGM1
mutations known to cause BSI, and the understanding of mutations related to
temperature sensitivity.
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METHODS
While working on genotype-phenotype characterization, we identified a cohort of
individuals with the limited phenotypic manifestations of BSI. I recruited and consented
several of these patients at the FIRST conference and the monthly ichthyosis clinics,
taking clinical photographs and obtaining saliva samples for genetic analysis. Several of
the patients were referred to us by dermatologists across the country and around the
world. The genetic analysis was performed by members of the Choate lab and the
referring physician in a few cases. I verified the Sanger sequencing traces for all of the
mutations in the cohort, identifying single nucleotide polymorphism (SNPs), referencing
mutations previously reported in the HGMD Professional Database and in the Exome
Aggregation Consortium, and determining which mutations are novel. I performed the
genotype-phenotype correlations reported in the study, identifying novel and recurrent
and determining which mutations are temperature-sensitive.

Subjects and samples
The study was approved by the Yale Human Investigation Committee, consistent with
the Declaration of Helsinki guidelines, and written informed consent was obtained from
the subjects or their parents. A detailed clinical history was obtained from each subject,
including phenotypic presentation at birth and evolution of disease when available. Selfreporting of ethnicity was obtained to evaluate founder effect. Saliva samples were
obtained from all of the subjects for genetic analysis.

Genetic analysis
Genetic analysis was performed on DNA isolated from saliva of index cases and both
parents, if available. DNA was extracted using standard procedures. Samples were
either screened for mutations in eleven genes including ABCA12, ALOXE3, ALOX12B,
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CYP4F22, NIPAL4, PNPLA1, SPINK5, TGM1, KRT1, KRT2E, and KRT10 via multiplex
PCR and next generation sequencing, or the coding exons of TGM1 were amplified
using polymerase chain reaction (PCR) and subsequently examined via Sanger
sequencing.

RESULTS
BSI phenotypes and TGM1 genotypes of each subject are described in Table 4.
Representative photos are provided in Figure 10 (Subjects 8 and 15), and the location
of mutations relative to TGM1 protein domains are shown in Figure 11.
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Table 4. TGM1 mutations causing BSI in sixteen subjects
Fourteen of 16 subjects presented at birth with a collodion membrane. All eventually
developed the characteristic phenotypic pattern seen in BSI, with scaling most prominent
on the scalp, neck and trunk and with sparing of the central face and distal extremities.
We report eight missense mutations not previously found in BSI. Five have been
previously shown to cause ARCI and three are novel mutations.
* Mutations not previously found in BSI
1
Novel mutations
Temperature-sensitive mutations are shown in red.
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Figure 10. Clinical features of BSI
Representative photos of the BSI phenotype, notable for plate-like scaling of the truck
and back, with sparing of the extremities and buttocks. (A) Subject 8. (B) Subject 15.
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Figure 11. Protein schematic of TGM1 mutations found in BSI
Thirteen mutations are located in the catalytic core, two in the ß-sandwich domain, and
one in the ß-barrel 2 domain. Nine lead to substitution of charged residues.
*

Mutations not previously described in BSI
Novel mutations
Temperature-sensitive mutations are shown in red.
1
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Homozygous TGM1 Arg264Trp, Arg286Gln, and Arg315Leu mutations are
temperature-sensitive
Subject 1 is the child of first cousins. He was born with a collodion membrane, and later
developed large brown scales on the back, chest and groin, with sparing of the face and
extremities. He is homozygous for a TGM1 Arg286Gln missense mutation. Arg286Gln
was previously reported in a compound heterozygous state with Gly278Arg (found in
Subject 9 and discussed below) in LI,51 but has not been previously reported in BSI.

Subjects 2 and 3 are siblings and the children of second cousins. Both were born with
normal skin at birth and no collodion membrane, and went on to develop plate-like scale
restricted to the neck, scalp, trunk, and flexural areas of upper extremities. Non-scarring
alopecia is present in both subjects. Both siblings are homozygous for a TGM1
Arg264Trp missense mutation, which has previously been found in a compound
heterozygous state in a patient with BSI.50 It was also found in a heterozygous state in
Patient 4, a female with TGM1 mutations Arg264Trp and Gly278Arg. The Gly278Arg
mutation has been previously described in both LI51 and in self-healing ichthyosis, a rare
form of ARCI characterized by the presence of a collodion membrane at birth with
spontaneous healing of the phenotype within the first few weeks.52, 53

Subjects 5 and 6 are African-American siblings, with no known consanguinity in the
family. Both were born with a collodion membrane and later developed plate-like scale
restricted to the scalp and truck. They are both homozygous for a TGM1 Arg315Leu
mutation, which has been reported by Arita et al. in a cohort of 8 South African BSI
subjects.54, 55
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The observation of homozygous mutations in these five subjects with BSI provides
evidence that these TGM1 mutations (Arg264Trp, Arg286Gln, and Arg315Leu) result in
temperature sensitivity. All fall within the catalytic core of the transglutaminase 1
enzyme (Figure 9).

Temperature-sensitive substitutions at R315 TGM1 are common compound
heterozygote mutations in BSI
Subjects 7 and 8 are siblings. Both were born with a collodion membrane and were
noted to have thickened, fragile skin at birth. They developed dark plate-like scaling,
most prominent on the back, chest, and neck. Both are compound heterozygous for
TGM1 Arg315Leu, a temperature-sensitive mutation described above, and Ser772Arg, a
novel mutation falling within the ß-barrel 2 domain (Figure 11).

Subject 9 is male born with a collodion membrane and ectropion. He now has brown
plate-like scales that are most prominent on the neck, scalp and trunk, with sparing of
the face and the extremities. He also exhibits attention deficit hyperactivity disorder and
developmental delay. He is compound heterozygous for TGM1 (Arg315His and
Gly278Arg). While both mutations fall within the catalytic core, Arg315His affects the
same residue as Arg315Leu (found in subjects 5-8 and described above), and has been
commonly reported in subjects with BSI.50, 56 The Gly278Arg mutation was also found in
Subject 4.

Subject 10 is a male born with a collodion membrane, and later developing scaling
restricted to the scalp and trunk. He has TGM1 mutations Arg315His and c.876+2 T>C,
a mutation within the donor splice site of exon 5 previously described in generalized
ARCI.57
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The observation of a missense mutation at R315 in six of our 16 BSI subjects highlights
the prevalence of substitutions at this site in BSI, and contributes to evidence that such
mutations are temperature-sensitive.

TGM1 Arg307Gly is a common BSI mutation and is temperature-sensitive
Subject 11 is a female born with a collodion membrane that peeled at a few weeks of
age, and developed thick dark scale on the scalp, neck, axillae, and groin by 1 year of
age. She is compound heterozygous for TGM1 Arg307Gly, which has been commonly
described in BSI,50,56 and c.877-2 A>G, a mutation within the acceptor splice site of exon
6, which has previously been found in BSI in conjunction with Arg307Gly (as in Subject
11) as well as with Arg264Trp and Arg315His in our cohort.50,56

Subject 12 is a male born with a collodion membrane. He now has brown plate-like
scales that are most prominent on the neck, scalp, axillae, and trunk. He is compound
heterozygous for TGM1 Gly218Ser and Arg307Gly. The Gly218Ser mutation has been
previously reported in an LI subject with a collodion membrane at birth and later
development of thick scales and ectropion.58

Subject 13 is a female born with a collodion membrane. She now has thick dark scale
restricted to the neck, scalp and truck. She has TGM1 mutations Arg307Gly and
Ser358Arg. The Ser358Arg mutation has been previously reported in two siblings with
LI, who were born with collodion membranes and later developed generalized scaling
with facial and palmoplantar involvement.59, 60

Marukian 49
Subject 14 is a female born with a collodion membrane, later developing scaling
restricted to the trunk and scalp. She has TGM1 mutations Arg307Gly and Tyr374Cys.
The Tyr374Cys mutation is within the catalytic domain and has not been described
previously.

The observation of the Arg307Gly mutation in four out of our sixteen BSI subjects
contributes to evidence that Arg307Gly is relatively common in BSI, and is a
temperature-sensitive mutation.

TGM1 Phe495Leu is a temperature-sensitive mutation
Subject 15 is a male born with a collodion membrane. He now has thick scale restricted
to the neck, scalp and truck, as well as flexural involvement of the extremities. He has
TGM1 mutations Arg143Cys and Phe495Leu. Homozygosity for the Arg143Cys mutation
has been previously described in two patients with LI.58 We therefore presume that
Phe495Leu, which is novel, is the temperature-sensitive mutation in this subject.

TGM1 Ile469_Cys471delinsMetLeu is a novel mutation in the catalytic core
Subject 16 is a female born with a collodion membrane. She now has scale restricted to
the neck, scalp and trunk. She has TGM1 mutations Gly291Asp and
Ile469_Cys471delinsMetLeu. The Gly291Asp mutation was previously described in a
compound heterozygous state in a patient with BSI,61 as well as a patient with
generalized ARCI.62 The TGM1 Ile469_Cys471delinsMetLeu is a novel in-frame indel
mutation that affects the catalytic core.
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DISCUSSION
BSI is a rare ARCI phenotype characterized by presentation at birth with a collodion
membrane, followed by clinical improvement of ichthyosis on the face and extremities
during the first few weeks of life. The resulting phenotype of scaling restricted to the
trunk, neck, and scalp is a distinguishing feature of BSI, and can be differentiated from
somatic mosaicism by the lack of a distribution pattern along Blaschko’s lines.

Prior to this report, 21 missense mutations had been reported in BSI subjects. Of these,
9 had been reported only in subjects with BSI, while 12 had been observed in both BSI
and generalized ARCI.62 Both truncating mutations (nonsense, splice site, and
frameshift) and missense mutations in TGM1 have been found in subjects with BSI.50, 54,
56, 61, 63, 64

However, while homozygosity or compound heterozygosity for truncating

mutations has been observed in generalized forms of ARCI,59, 65, 66 such a genotype has
never been observed in BSI. This is consistent with the hypothesis that near or total loss
of TGase-1 function causes generalized forms of ARCI, while genotypes that include a
missense mutation resulting in a partially active, temperature-sensitive TGase-1 result in
the more limited BSI phenotype.

In 2006, Oji et al. investigated TGase-1 enzymatic activity in BSI tissue, assessing
uptake of biotinylated cadaverine into cornified envelopes, finding that areas of healthy
skin in patients with BSI show nearly normal TGase-1 activity, while affected areas
display clearly reduced and abnormal activity. Furthermore, digital thermal imaging
showed close association between skin temperature and the degree of scaling in
patients with BSI, with warmer body sites exhibiting greater scaling. Functional TGase-1
testing of normal-appearing skin of a BSI subject homozygous for the missense mutation
Tyr276Asn showed clear temperature-sensitivity, with reduction in enzyme activity at
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37˚C compared to 25˚C. This may explain the increased degree of scaling at sites of
relatively higher temperature, such as the trunk.50

In addition to the TGM1 mutation Tyr276Asn, several other mutations have been
previously presumed to be temperature-sensitive based on their presence in a
homozygous state in subjects with BSI, including TGM1 mutations Ile304Phe,
Arg307Gly, Arg315Leu, Arg315His, Val383Met, Arg687His.50, 54-56, 61, 63, 67

Here we report phenotypic and genotypic data from 16 subjects with BSI, the largest
cohort published to date. Aside from a pair of siblings who had normal skin at birth with
no collodion membrane (subjects 2 and 3), the phenotypes were consistent with prior
descriptions of BSI. We identified a total of 16 unique mutations in our cohort, including
13 missense, two splice site, and one indel mutation. Eight of the missense mutations
have not been previously reported for BSI; of these, five have been previously described
in generalized ARCI (Arg143Cys, Gly218Ser, Gly278Arg, Arg286Gln, Ser358Arg), while
three (Tyr374Cys, Phe495Leu, Ser772Arg) are novel mutations. The indel mutation
TGM1 I469_C471delinsML is also novel.

Tranglutaminase 1 consists of three domains: an N-terminal ß-sandwich domain, a
catalytic core domain, and two C-terminal ß-barrel domains.68 Most BSI mutations have
been located in exons 5 and 6 of TGM1, encoding the N-terminal portion of the catalytic
core domain.50 Of the 13 unique missense mutations reported in this study, only two are
within the ß-sandwich domain (Arg143Cys, Gly218Ser) and one is within the ß-barrel 2
domain (Ser772Arg). In stark contrast, ten are within the catalytic core (Arg264Trp,
Gly278Arg, Arg286Gln, Gly291Asp, Arg307Gly, Arg315His, Arg315Leu, Ser358Arg,
Tyr374Cys, Phe495Leu), including all three of the mutations homozygous in our BSI
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subjects. (Figure 9). All of our BSI subjects have at least one mutation within the
catalytic core, and catalytic core mutations represent 88% of the mutations in our
unrelated probands (23 of 26 alleles). Given that the catalytic core is only 38% of the
total protein, our findings underscore a striking clustering of BSI mutations in this
domain.

Based on our observation of BSI subjects homozygous for TGM1 mutations Arg264Trp,
Arg286Gln, and Arg315Leu, we conclude that these mutations are temperaturesensitive. Furthermore, the recurrence of mutations affecting R307 and R315 in our
cohort, which among unrelated probands are present in 1/3 of homozygotes and 7/10 of
compound heterozygotes, comprising 35% of the mutations (9 out 26 total alleles),
bolsters prior evidence that these mutations are common in BSI (also reported by
Bourrat et al.),56 and temperature-sensitive. Finally, we hypothesize that the novel
mutation Phe495Leu is temperature-sensitive, given that the TGM1 genotype of subject
15 includes this mutation and Arg143Cys; the latter mutation is presumably not
temperature-sensitive given that subjects homozygous for Arg143Cys are described as
exhibiting generalized LI.58

Though our findings provide evidence for temperature sensitivity of TGM1 mutations,
clear genotype-phenotype correlations have been difficult to establish, as several TGM1
mutations have been reported in both BSI and generalized ARCI. For example,
homozygosity for Arg315Leu has been found in a pair of twins who were described as
having lamellar ichthyosis, whose phenotype at two months of age included thick platelike scaling affecting the truck and extremities, with sparing of the face.69 Another patient
described as having characteristic phenotypic findings of lamellar ichthyosis was found
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to be compound heterozygous for TGM1 mutations, including Arg286Gln, which we
describe here as temperature-sensitive.51

The reporting of these mutations in both BSI and generalized ARCI may represent
evolution of the phenotype, as patients with BSI can present with more generalized
scaling earlier in life, with appearance of a bathing-suit distribution later in childhood.
Thus, phenotypic characterization within the first few months of life may lead to
misclassification. This dynamic nature of BSI highlights the importance of continued
follow-up of subjects with presumed temperature-sensitive mutations, with phenotypic
re-evaluation at multiple ages. Additional environmental or genetic factors that may
determine the level of enzyme activity and response to temperature in subjects with
TGM1 mutations remain unclear.

Patients with BSI typically respond well to agents that improve barrier function and
promote desquamation, including keratolytics and topical or systemic retinoids. Topical
tazarotene led to substantial improvement in two subjects within our cohort.

Our findings expand the genotypic spectrum of BSI, and provide evidence supporting the
temperature sensitivity of specific TGM1 mutations (Arg264Trp, Arg286Gln, Arg307Gly,
Arg315Leu, Arg315His, Phe495Leu), which are clustered in the catalytic core. Although
patients respond well to topical and systemic therapies, further research into the
pathogenesis of BSI could lead to the development of novel therapeutic approaches
targeting enzymatic stability and consideration of environmental modifications that might
modify disease severity.
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Chapter 3: Establishing and Validating an Ichthyosis Severity Index

ABSTRACT

We designed and validated a Visual Index for Ichthyosis Severity (VIIS) for scale and
erythema that provides 1) written descriptions of the features characteristic of each level
of severity 2) visual standards for 4 body sites, and 3) two distinct standards to account
for different types of scale. We tested the VIIS for reliability and reproducibility using two
different settings: one that utilized scoring of 60 test photographs by 10 dermatologists,
and one with in-person evaluations on 85 subjects by 12 dermatologists at the
Foundation for Ichthyosis and Related Skin Types (FIRST) conference. The validation
process revealed high reliability and reproducibility for both scale and erythema. The
inter-rater and intra-rater ICCs for scale were consistently near or greater than 0.7 in
both settings. By contrast, the inter-rater reliability for erythema was higher during inperson validation compared to validation on test photographs. Our analysis indicates
that the VIIS performs better in person than with photographs, an important
consideration in design of clinical trials. Power analysis predicts that a 1-step difference
on this 5-step scale would be detectable with 12 subjects in each of two defined groups.
This index provides a tool for clinical phenotyping and assessment of therapeutic
response for many disorders of keratinization.
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INTRODUCTION
Careful examination of patients who have ichthyosis reveals that the amount of scale on
specific sites is quite variable, and that there are subtle differences in the quality of scale
between different genotypes. While textbooks often suggest a monomorphous
presentation for different types of ichthyosis, our experience from carefully
photographing and genotyping over 500 individuals with ichthyosis shows significant
patient to patient variability in amount of scale at any given body site. Previous
estimates of scale severity have been limited by focus on a single body site,71 by
examples of severity that utilize different body sites as comparators,72 or by
concentration on a single phenotype.73

Erythema is often a clinically significant component of ichthyosis even though the
relative roles of vasodilation and inflammation are not well understood. Erythema is an
important component of many skin diseases, but there is no agreement as to how its
severity should be measured. Strong arguments have been made for the clinical validity
of visual analog scales,74, 75 or the superiority and sensitivity of reflectance
spectroscopy.76-78 To our knowledge, all measurements of erythema in ichthyosis have
used a visual analog scale without critical validation.

A reliable method of assessing the clinical severity of subjects with ichthyosis is critical
to evaluating the efficacy of new treatments and to grading the severity of ichthyosis due
to mutations in a single gene and between different genes. Although prior studies have
used visual scales to measure the clinical severity of this rare group of disorders,71-73, 79,
80

to date, no widely-accepted index exists.
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Our goal was to develop a severity index that could be used across many types of
ichthyosis and many body sites without requiring separate scales for each body site,
genotype or phenotype.
We aimed to create severity index using photographs and detailed written descriptions
for the degree of scale and erythema in ichthyosis.

We designed a prospective study to evaluate the reliability and reproducibility our
instrument, the Visual Index for Ichthyosis Severity (VIIS), using two different settings:
one that utilized scoring of test photographs and one with in-person evaluations.

METHODS
While working on the genotype-phenotype characterization, we identified the need for a
reliable method to assess ichthyosis severity. Working with Dr. Choate and Dr. Milstone,
we identified photographs that were representative of each level of severity, and created
detailed written descriptions for each level of severity. I recruited and consented patients
at the FIRST conference and the monthly ichthyosis clinics, taking standardized clinical
photographs. Working with Dr. Choate and Dr. Milstone, I led both stages of validation.
Statistical analysis was performed by Yanhong Deng and Geliang Gan from the Yale
Center for Analytical Sciences.

Study Design
To design a user-friendly tool, we developed photographic standards for two
characteristics of ichthyosis: scale and erythema. For scale, photographic standards for
four representative body sites that are typically less aggressively groomed (upper arm,
upper back, lower leg and dorsal foot) were created. Each of the four representative
body sites was carefully defined using anatomical landmarks. Two different sets of scale
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standards were developed: the lamellar (“L”) set of standards for the typical flat scales
that are seen in most forms of ichthyosis and the keratoderma (“K”) set for the more
columnar scales that are typical of epidermolytic ichthyosis and erythrokeratodermas.
We employed five-point Likert scales (0-4) with increasing clinical severity. The
combined scores, therefore, range from 0 to 16 (score of 4 for all 4 body sites) for each
category (erythema and scale). The final score accounts for both erythema and scale,
and ranges from 0 to 32. Each photographic standard includes representative clinical
photographs for each severity score, along with detailed written descriptions of features
characteristic of the severity score represented. All of the clinical photographs were
obtained at Foundation for Ichthyosis and Related Skin Types (FIRST) family
conferences. The photographs included in the standards were limited to subjects with
Fitzpatrick 1-3 skin type. Photographs were chosen with the aim of demonstrating
severity alone. All of the photographic standards can be found in the Appendix.

Validation of our instrument was performed in two stages the first utilized scoring of test
photographs, and the second involved in-person evaluations. During the first stage, ten
dermatologists were provided with a series of 60 test photographs (15 photographs for
each of the 4 body sites) and asked to independently use our index to score for scale
and erythema (Stage 1, Round 1). The re-shuffled photographs were sent to the same
dermatologists four weeks later (Stage 1, Round 2) to determine intra-rater reliability.
This four-week interval was chosen to reduce rater recall of prior scoring.71

The second stage of validation was performed at the FIRST family conference in San
Diego in June 2016. Eligible participants included all subjects enrolled in the National
Registry for Ichthyosis and Related Skin Types who participated in a clinical screening
appointment at the conference. None refused to participate. Subjects were seen in one
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of three clinical evaluation rooms with four dermatologists assigned to each room. A total
of twelve dermatologists participated, and they were asked to independently rate the
clinical severity of the subjects seen in their room. The rating process was limited to the
first 5 minutes of each twenty minute appointment. Discussion of ratings was not
permitted and all raters attested that they adhered to this requirement. Four (two in room
2 and two in room 3) out of the twelve dermatologists had previously participated as
raters during the validation on test photographs.

Participants

The study was approved by the Yale Human Investigation Committee, consistent with
the Declaration of Helsinki guidelines, and written informed consent was obtained from
the participants or their parents. Each participant was asked to fill out a questionnaire,
including self-reporting of gender, age, ethnicity, and ichthyosis type.

Statistical analysis

Intra-rater Intraclass Correlation Coefficients (ICCs) for agreement were estimated using
the one-way random model. The estimated ICCs are the variances contributed by the
different subjects divided by the summation of variances contributed by subjects and the
variances of random error. Combined intra-rater ICCs were estimated using the mixed
model controlling for raters. Inter-rater ICCs for agreement were estimated using the
two-way random model. The estimated ICC is the variance contributed by the different
subjects divided by the summation of the variance contributed by subjects, variance
introduced by the raters and the variance of random error. Inter-rater ICCs for
consistency were estimated using the two-way random model as well. The estimated
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ICC is the variance contributed by the different subjects divided by the summation of the
variance contributed by the subjects and the variance of random error. ICCs less than
0.7 were considered unacceptable, 0.7 – 0.79 fair, 0.8 – 0.89 good, and greater than or
equal to 0.9, excellent.11 The reliability of choosing the “L” or “K” standard by the same
rater was estimated by the Cohen’s Kappa, which is a measure of intra-rater reliability
for a nominal variable. The reliability of choosing the “L” or “K” standard on same subject
across all raters was estimated by the Kuder-Richardson Formula 20, which is a
measure of inter-rater reliability for a nominal variable. All confidence intervals were
calculated at 95% confidence level. For the power analysis, a two-sided two-sample ttest was performed with a significance level (alpha) of 0.05. All analyses were carried
out using SAS 9.4.3 (SAS Institute, Cary, NC).

RESULTS

Validation of VIIS on test photographs (Stage 1)

A total of 60 photographs (15 for each body site) were sent to ten dermatologists for
baseline scoring (Stage 1, Round 1). All raters were experts in ichthyosis, and members
of the FIRST Medical & Scientific Advisory Board (MSAB). The re-shuffled photographs
were re-sent in four weeks to test reproducibility (Stage 1, Round 2). Demographic and
clinical details for the subjects whose photographs were used as the test images can be
found in Table 5.
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Upper Back

Upper Arm

Lower Leg

Dorsal Foot

Total
n

Gender

Ethnicity

Age

%

Male

5

6

5

5

21

35.0%

Female

10

9

10

10

39

65.0%

Caucasian

12

11

11

11

45

75.0%

Hispanic/Latino

1

1

0

1

3

5.0%

Black

0

1

1

0

2

3.3%

Unknown

2

2

3

3

10

16.7%

≥ 18 yrs

9

8

6

7

30

50.0%

< 18

6

7

9

8

30

50.0%

EI

5

4

6

6

21

35.0%

ARCI

6

7

6

7

26

43.3%

Netherton's

1

0

0

1

2

3.3%

Ichthyosis vulgaris

0

1

1

0

2

3.3%

Normal control

1

1

0

0

2

3.3%

Unclassified

2

2

2

1

7

11.7%

Ichthyosis Type

Table 5. Demographic and clinical characteristics for patients whose photographs
were used for the first stage of validation (n=60)
Abbreviations: EI, Epidermolytic Ichthyosis; LI, Lamellar Ichthyosis; CIE, Congenital
Icthyosiform Erythroderma.
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Inter-rater reliability was higher for scale than for erythema
Descriptive statistics for inter-rater reliability (IRR) for scale and erythema can be found
in Figure 12. Two measures of IRR were evaluated: ICC for agreement, which is the
more rigorous metric and requires absolute agreement among the raters, and ICC for
consistency, which measures whether the raters provide scores that have the same rank
order rather than requiring agreement on the absolute values. ICCs for consistency are
especially relevant when evaluating a change in severity from baseline, such as
assessing response to treatment. As expected, ICCs for consistency are higher than
ICCs for agreement for the same data points. For both rounds 1 and 2, the ratings were
found to be significantly correlated for scale (ICCs near 0.7 or greater). However, the
inter-rater reliability for erythema was poor (ICCs < 0.7).

Raters were consistent in choosing the specific set of scale standards for a given subject
Raters were given two separate sets of scale standards (lamellar or “L” set of standards
and keratoderma or “K” set of standards) to account for the two different types of scales
most commonly seen in subjects with ichthyosis. Raters were consistent in choosing a
set of standards (“L” or “K”) for a given patient, and there was excellent inter-rater
reliability for all body sites during both rounds of testing (Kuder-Richardson Formula 20 >
0.9) Table 6. There was also high intra-rater reliability between Round 1 and Round 2
for the same rater, with Kappa near or greater than 0.7 for all body sites.

Intra-rater reliability was higher for scale compared to erythema
To determine intra-rater reliability, we employed a test-retest approach with a 4-week
interval between Rounds 1 and 2. Across all ten raters, the intra-rater ICC was 0.75 (CI
0.60, 0.90) for scale and 0.59 (CI 0.39, 0.79) for erythema.
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Figure 12. IntraClass Correlation Coefficients (ICCs) for agreement and
consistency for the two rounds of photographic testing (Stage 1, Rounds 1 and 2)
For both rounds of testing, the ratings were significantly correlated for scale (ICCs near
0.7 or greater). The inter-rater reliability for erythema was lower (ICCs less than 0.7).
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ROUND 1

ROUND 2

Dorsal Foot

0.95 (0.89, 0.98)

0.95 (0.89, 0.98)

Lower Leg

0.94 (0.88, 0.98)

0.91 (0.82, 0.96)

Upper Arm

0.90 (0.81, 0.96)

0.92 (0.83, 0.97)

Upper Back

0.92 (0.85, 0.97)

0.94 (0.89, 0.98)

Table 6. Kuder-Richardson Formula 20, KR20, values for the two rounds of
photographic testing (Stage 1, Rounds 1 and 2)
Raters were consistent in choosing the specific set of standards for scale (“L” or “K”) for
a given patient, with excellent inter-rater reliability for all body sites (KR20 > 0.9).
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Live validation of VIIS at the FIRST conference (Stage 2)

A total of 85 subjects (27 in Room 1, 27 in Room 2, 31 in Room 3) were enrolled in the
study and evaluated by three or four dermatologists. Demographic and clinical details for
all subjects can be found in Table 7.

Inter-rater reliability was high for both scale and erythema
Descriptive statistics for inter-rater reliability (IRR) for scale and erythema can be found
in Figure 13. Across all rooms, the scores were found to be highly correlated for both
scale and erythema, with ICCs near or greater than 0.7. The inter-rater reliability for
scale was generally greater than that for erythema. The scores in Room 1 showed the
highest degree of inter-rater reliability, with ICCs greater than 0.7 for both scale and
erythema for all 4 body sites.

Raters were consistent in choosing the specific set of scale standards for a given subject
Similar to the data from validation on test photographs discussed above, the raters were
consistent in choosing the specific set of scale standards (“L” or “K”) for a given subject.
The inter-rater reliability was high with Kuder-Richardson Formula 20 greater than 0.77
for all body sites Table 8. In room 2, all of the raters unanimously agreed on “L” or “K”
for all of the subjects seen (Kuder-Richardson Formula 20 of 1).

Inter-rater reliability was high for the combined scores for scale and erythema, as well as
the final total scores
An important feature of the design of our index is the ability to allow for a comprehensive
assessment of ichthyosis severity that accounts for the severities at the 4 representative
sites. We determined IRR for the combined scores that range from 0 to 16 (score of 0-4
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for each of 4 body sites) for each category (erythema and scale). We also determined
IRR for the final score (sum of combined scores for scale and erythema) that ranges
from 0 to 32. As shown in Figure 14, the inter-rater reliability was high, with ICCs
consistently higher than 0.7.

Power analysis to predict sample size for 1-step improvement
To determine the feasibility of using VIIS in future clinical trials, we performed a power
analysis to determine the number of subjects that would need to be enrolled to detect a
single step improvement or decrement on our 5-step scale. For our cohort of 85
subjects, the mean scores for erythema and scale are 1.78 and 2.35, respectively,
across all body sites. In many clinical trials, inclusion criteria require subjects to start with
a severity of at least 2 to measure a 1-2 step improvement. Approximately 50% and 70%
of subjects had scores greater than or equal to 2 for erythema and scale, respectively.
For subjects with average scores greater than or equal to 2, the mean score was 2.8
with standard deviation of 0.7. Given the null hypothesis that the control and treatment
groups have equal means of 2.8, the alternative hypothesis that the mean of the
treatment group is 1.8 (1 unit difference), and an estimated group standard deviations of
0.7, a sample sizes of 12 in the control group and 12 in the treatment group will achieve
92% power to detect a one unit difference.
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Room 1

Room 2

Room 3

Total
n

Gender

Ethnicity

Age

Ichthyosis Type

%

Male

12

16

11

39

45.9%

Female

15

11

20

46

54.1%

Caucasian

21

19

26

66

77.6%

Hispanic/Latino

2

1

2

5

5.9%

Black

1

1

0

2

2.4%

Asian

2

4

1

7

8.2%

Unknown

1

2

2

5

5.9%

≥ 18 yrs

19

14

9

42

49.4%

< 18

6

8

21

35

50.6%

EI

6

6

9

21

24.7%

ARCI

9

8

13

30

35.3%

Netherton's

0

2

4

6

7.1%

X-linked ichthyosis

1

1

0

2

2.4%

Ichthyosis vulgaris

1

1

1

3

3.5%

HI

0

2

1

3

3.5%

IWC

2

0

0

2

2.4%

EKV

1

0

0

1

1.2%

KID syndrome

1

0

0

1

1.2%

Unclassified

6

7

3

16

18.8%

Table 7. Demographic and clinical characteristics for patients enrolled in the
second stage of validation at the FIRST conference (n=85)
Abbreviations: EI, Epidermolytic Ichthyosis; LI, Lamellar Ichthyosis; CIE, Congenital
Icthyosiform Erythroderma; HI, Harlequin Ichthyosis; IWC, Ichthyosis With Confetti; EKV,
Erythrokeratoderma Variabilis.
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Figure 13. IntraClass Correlation Coefficients (ICCs) for agreement and
consistency for the three rooms during in-person evaluations at the FIRST
conference (Stage 2)
For all rooms, the ratings were found to be highly correlated for scale and erythema
(ICCs near 0.7 or greater).
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ROOM 1

ROOM 2

ROOM 3

Dorsal Foot

0.85 (0.72, 0.92)

1.00 (1.00, 1.00)

0.94 (0.89, 0.97)

Lower Leg

0.85 (0.73, 0.92)

1.00 (0.99, 1.00)

0.92 (0.87, 0.96)

Upper Arm

0.77 (0.59, 0.88)

1.00 (0.99, 1.00)

0.92 (0.87, 0.96)

Upper Back

0.83 (0.69, 0.91)

1.00 (1.00, 1.00)

0.92 (0.86, 0.96)

Table 8. Kuder-Richardson Formula 20, KR20, values for the three rooms during
in-person evaluations at the FIRST conference (Stage 2)
Raters were consistent in choosing the specific set of standards for scale (“L” or “K”) for
a given patient, with KR20 greater than 0.77 for all body sites.

Marukian 69

0.6 0.8

0.6 0.8

0.6 0.8

Figure 14. IntraClass Correlation Coefficients (ICCs) for agreement and
consistency for the combined scores for scale and erythema, as well as the final
total scores during in-person evaluations at the FIRST conference (Stage 2)
For all rooms, the ratings were found to be highly correlated for hyperkeratosis and
erythema (ICCs greater than 0.7).
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DISCUSSION
We have designed and validated a visual severity index for ichthyosis, a critical tool for
research and clinical evaluation in this rare group of disorders. The Congenital
Ichthyosis Severity Index (CISI) is the only other ichthyosis severity index to have
undergone validation. Similar to our instrument, the CISI employs visual Likert scales for
scale and erythema.72 We aimed to improve the convenience and applicability of the
index by providing 1) clear written descriptions of the features characteristic of each level
of scale 2) visual standards for four different body sites, and 3) two different sets of scale
standards to account for two different types of scale seen in subjects with ichthyosis.

To create a user-friendly index, we focused on two different types of scale (lamellar and
keratoderma), instead of creating a separate standard for each subtype of ichthyosis as
was done for the CISI.80 We found high inter-rater and intra-rater ICCs for scale (near
0.7 or greater for all rounds of testing). Raters were highly consistent in deciding which
set of scale standards to choose for a given subject (Kuder-Richardson Formula 20
greater than 0.77 for all rounds of testing), even though our subject population was
heterogeneous with respect to clinical diagnosis (Table 5 and Table 7). Subgroup
analysis revealed that high ICCs for scale were maintained even in the rare cases where
raters disagreed on which set of standards to use for a given subject; that is, ICCs for
subjects for whom all the raters unanimously chose the same set of standards did not
differ significantly from ICCs for subjects for whom raters chose differently. This
indicates that our two different sets of scale standards capture increments of severity in
a similar fashion, possibly due to the detailed written descriptions that standardize the
scoring regardless of which set of standards is used. This suggests that the
standardized written descriptions may allow or even be critical for scoring of the many
different clinical subtypes of ichthyosis—even those not represented in the photographs.
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While the inter-rater reliability for erythema was high (ICCs near 0.7 or greater) during inperson validation at the FIRST conference, it was poor (ICCs less than 0.6) during
validation on test photographs. This finding emphasizes the difficulty of capturing and
reproducing erythema on photographic images. Many factors, including room lighting
and color saturation settings, can impede consistent evaluation of erythema on
photographs.

Much literature has been published on evaluation of erythema, with compelling evidence
for the use of both visual analog scales, and more objective methods, such as
reflectance spectrophotometry. Reflectance spectrophotometry calculates an erythema
index by comparing the intensity of light absorbed by hemoglobin (green light) to that of
light absorbed by melanin (red light). Several studies have provided evidence for the
reliability of reflectance spectrophotometry;77,78 however, others have shown lack of
superiority of readings from a reflectance spectrophotometry compared to visual analog
scales.75, 82 Various operator factors can influence the reading obtained from reflectance
spectrophotometry, including the pressure with which the instrument is held and the
angle used.83 Furthermore, several individual factors can impact reflectance
spectrophotometry readings, including blood pressure, smoking, caffeine intake, and
skin phototype.83,84 Latreille et al. showed that erythema induced by methyl nicotinate
was not detected by reflectance spectrophotometry in the darker phototypes, possibly
because the emitted light is predominantly absorbed by the melanin in the epidermis and
does not reach the hemoglobin in the dermis.84 Given the time- and cost-effectiveness of
visual observation, and lack of strong evidence for the superiority of reflectance
spectrophotometry, we utilized a visual analog scale for the evaluation of erythema in
our index.
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During in-person evaluation, our index showed high inter-rater reliability for both
erythema and scale with ICCs near 0.7 and greater. An important feature the VIIS is its
flexibility in either evaluating the severity at a specific individual body site, as may be
done in a clinical trial, or utilizing ratings of all 4 body sites to arrive at a comprehensive
assessment of ichthyosis severity. Our analysis showed high inter-rater reliability for
both the individual ratings for each body site, as well as the combined scores.

A limitation of our index is that the photographs included in the standards were from
subjects with Fitzpatrick I-III skin type. As shown in Table 5 and Table 7, the majority of
the subjects during the validation process were Caucasian. Ideally, visual standards
would have been created for a range of skin phototypes. We aimed to increase the
generalizability of our instrument while maintaining convenience by including written
descriptions for each level for severity that are applicable to all skin types. Further
studies will be necessary to determine whether our standards can be reliably used for
Fitzpatrick IV-VI skin types, especially for erythema since evaluation of erythema can be
more challenging in individuals with darker phototypes.

We have designed a Visual Index for Ichthyosis Severity (VIIS), and performed several
rounds of rigorous validation to show high reliability and reproducibility. Such a
standardized method of assessing disease severity has the potential to advance
ichthyosis research. This user-friendly index was easily applied by dermatologists during
a busy schedule of clinical evaluations at the FIRST conference, and with high ICCs for
evaluation of scale and erythema. Our analysis also indicates that to reliably capture all
aspects of the index, it is essential that the evaluations be performed in person. This
finding is critical to the study design of clinical trials and emphasizes the importance of
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in-person evaluations rather than assessments of photographs, especially when
erythema is one of the outcome measures. In addition, power analysis revealed that a
sample size of 24 (12 in control group, 12 in treatment group) will achieve 92% power in
detecting a unit difference, which is a feasible sample size. We expect this index to
facilitate clinical phenotyping and to provide a measure of response for therapeutic trials
which assess the cardinal features of this class of disorders.
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